Rise and shine, everyone, another busy day is on the way. Once again, however, events conspired to delay us this morning, thanks to some technology woes. Nonetheless, we are persevering thanks to a fresh cup or two of stimulation — our choice today is salted caramel mocha. Reminds us of the Jersey shore. Meanwhile, here are some items of interest to stimulate you. We hope your journey today is successful and remind you that our door remains open for saucy tips and secret dossiers. And of course, stay safe — wear a mask …

Russia’s Sputnik V vaccine showed high efficacy and safety levels in a peer-reviewed study, a potential boost for the Kremlin’s aim to promote the Covid-19 shot abroad and curb the pandemic at home, The Wall Street Journal says. The findings, from a preliminary analysis of a large-scale clinical trial published in The Lancet, demonstrated 91.6% efficacy against symptomatic Covid-19 and offered complete protection against severe cases. There were no serious side effects and similar safety and efficacy was found in older adults.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]